Taiwan's Jyong Biotech Raises $20M in Nasdaq IPO to Advance Botanical Urinary Disease Treatments
Key Insights
Jyong Biotech Ltd. (search), a Taiwan-based biotechnology company specializing in plant-derived drugs for urinary system diseases (search), successfully priced its initial public offering at $7.50 per share, raising approximately $20 million in gross proceeds.
The company will allocate 40% of net proceeds to fund additional Phase III trials of its lead botanical drug candidate MCS-2 and its new drug application, representing the largest portion of the IPO funding strategy.
Jyong Biotech's ordinary shares are expected to commence trading on the Nasdaq Global Market under ticker symbol "MENS" on June 17, 2025, marking a significant milestone for the 23-year-old company founded in 2002.
Taiwan-based Jyong Biotech Ltd. (search) successfully completed its initial public offering on June 16, 2025, pricing 2,666,667 ordinary shares at $7.50 per share to raise approximately $20 million in gross proceeds before underwriting discounts and expenses. The biotechnology company, which specializes in developing plant-derived drugs for urinary system diseases (search), will begin trading on the Nasdaq Global Market under the ticker symbol "MENS" on June 17, 2025.
Strategic Focus on Botanical Drug Development
Founded in 2002, Jyong Biotech has established itself as a science-driven biotechnology company with integrated capabilities spanning drug discovery, clinical trials, regulatory affairs, manufacturing, and commercialization. The company's proprietary platform focuses on developing botanical drug candidates primarily targeting urinary system diseases (search), with initial market focus on the United States, European Union, and Asia.
The company's pipeline includes its primary botanical drug candidate MCS-2, along with other clinical-stage and preclinical-stage botanical drug candidates. Since inception, Jyong Biotech has built comprehensive drug development capabilities encompassing all key functionalities from early-stage discovery through commercialization.
IPO Proceeds Allocation Strategy
The net proceeds from the offering will be strategically allocated across multiple development programs. The largest portion, representing 40% of funds, will support additional Phase III trials of MCS-2 (API-2) and the new drug application for MCS-2. An additional 25% has been earmarked for funding earlier phase trials if the company cannot demonstrate comparability.
The remaining funds will support the company's broader pipeline development, with 10% allocated to Phase II trials of PCP, 5% designated for Phase I clinical trials of IC (search), and 20% reserved for general corporate purposes. This allocation reflects the company's commitment to advancing its lead program while maintaining support for earlier-stage candidates.
Market Entry and Financial Structure
The offering includes an over-allotment option granting underwriters the right to purchase up to an additional 400,000 ordinary shares within 45 days of the final prospectus at the public offering price, less underwriting discounts. Joseph Stone Capital, LLC (search) serves as the sole underwriter for the firm commitment offering.
The company's registration statement on Form F-1 (File No. 333-277725) was declared effective by the U.S. Securities and Exchange Commission on June 16, 2025. The offering is expected to close on June 18, 2025, subject to customary closing conditions.
Regulatory and Legal Framework
Sichenzia Ross Ference Carmel LLP serves as U.S. securities counsel to Jyong Biotech, while VCL Law LLP represents the underwriter in connection with the offering. The company has filed comprehensive documentation with the SEC, with prospectus copies available through Joseph Stone Capital, LLC (search) and the SEC's website.
WFS Investor Relations Inc. (search), with Managing Partner Janice Wang, handles investor relations for the company, providing ongoing communication channels for stakeholders and potential investors in the newly public biotechnology company.